MCID: PRS080
MIFTS: 26

Prostate Cancer, Hereditary, 7

Categories: Cancer diseases, Reproductive diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Prostate Cancer, Hereditary, 7

MalaCards integrated aliases for Prostate Cancer, Hereditary, 7:

Name: Prostate Cancer, Hereditary, 7 53 13 69
Prostate Cancer Aggressiveness 53
Hpc7 53

Classifications:



External Ids:

OMIM 53 610321
MedGen 39 C1853195
UMLS 69 C1853195

Summaries for Prostate Cancer, Hereditary, 7

MalaCards based summary : Prostate Cancer, Hereditary, 7, also known as prostate cancer aggressiveness, is related to prostate cancer aggressiveness quantitative trait locus on chromosome 19 and prostate cancer. An important gene associated with Prostate Cancer, Hereditary, 7 is HPC7 (Prostate Cancer, Hereditary, 7). The drugs Selenium and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include prostate and bone.

Description from OMIM: 610321

Related Diseases for Prostate Cancer, Hereditary, 7

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 7

Clinical features from OMIM:

610321

Drugs & Therapeutics for Prostate Cancer, Hereditary, 7

Drugs for Prostate Cancer, Hereditary, 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
2
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
3
Olaparib Approved Phase 2 763113-22-0 23725625
4
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
5
Cholecalciferol Approved, Nutraceutical Phase 2 67-97-0 10883523 5280795 6221
6
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
7
Lycopene Approved, Investigational, Nutraceutical Phase 2 502-65-8 446925
8 Tocopherol Approved, Investigational, Nutraceutical Phase 2
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
10
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
11 Antioxidants Phase 2
12 Bone Density Conservation Agents Phase 2
13 Carotenoids Phase 2
14 Ergocalciferols Phase 2
15 Micronutrients Phase 2
16 Protective Agents Phase 2
17 Radiation-Protective Agents Phase 2
18 Tocopherols Phase 2
19 Tocotrienols Phase 2
20 Trace Elements Phase 2
21 Vitamins Phase 2
22 Anti-Inflammatory Agents Phase 2
23 Antineoplastic Agents, Hormonal Phase 2
24 glucocorticoids Phase 2
25 Hormone Antagonists Phase 2
26 Hormones Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
28 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
29 Calciferol Nutraceutical Phase 2
30 Tea Nutraceutical Phase 2
31 Tocotrienol Investigational, Nutraceutical Phase 2 6829-55-6
32 Vitamin D2 Nutraceutical Phase 2
33 Antibodies
34 Antigen-Antibody Complex
35 Immunoglobulins

Interventional clinical trials:

(show all 11)

# Name Status NCT ID Phase Drugs
1 Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate Cancer Completed NCT00844792 Phase 2 Placebo
2 Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC Recruiting NCT03263650 Phase 2 Cabazitaxel;Carboplatin;Prednisone 5Mg;Olaparib
3 Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness Completed NCT03289130
4 Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer Completed NCT01780701
5 Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness Recruiting NCT02545881
6 MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness Recruiting NCT01464216
7 Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer Recruiting NCT02745496
8 Structural Network on Prostate Cancer in the French Greater West Region Recruiting NCT03214315
9 Biobank for African American Prostate Cancer Research in Florida Recruiting NCT03232411
10 Magnetic Resonance Spectroscopic Imaging of the Prostate at 3 Tesla Active, not recruiting NCT00588679
11 Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial Not yet recruiting NCT03413007

Search NIH Clinical Center for Prostate Cancer, Hereditary, 7

Genetic Tests for Prostate Cancer, Hereditary, 7

Anatomical Context for Prostate Cancer, Hereditary, 7

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 7:

38
Prostate, Bone

Publications for Prostate Cancer, Hereditary, 7

Articles related to Prostate Cancer, Hereditary, 7:

(show all 27)
# Title Authors Year
1
Core 2 I^-1, 6-N-acetylglucosaminyltransferase-1 expression in prostate biopsy specimen is an indicator of prostate cancer aggressiveness. ( 26768364 )
2016
2
Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population. ( 26754263 )
2016
3
Trinucleotide repeat length in the first exon of the androgen receptor gene may be associated with prostate carcinogenesis and facilitate prediction of prostate cancer aggressiveness. ( 26895311 )
2016
4
Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts. ( 25595908 )
2015
5
HES6 promotes prostate cancer aggressiveness independently of Notch signalling. ( 25864518 )
2015
6
Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes. ( 25307492 )
2015
7
Association of genetic polymorphisms in the telomerase reverse transcriptase gene with prostate cancer aggressiveness. ( 25738283 )
2015
8
Urinary nerve growth factor as an oncologic biomarker for prostate cancer aggressiveness. ( 24794250 )
2014
9
Comparative evaluation of urinary PCA3 and TMPRSS2: ERG scores and serum PHI in predicting prostate cancer aggressiveness. ( 25079439 )
2014
10
Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressiveness. ( 24907642 )
2014
11
Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. ( 25277178 )
2014
12
Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans. ( 22549899 )
2013
13
Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression. ( 23308245 )
2013
14
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. ( 22025384 )
2012
15
Leptin increases prostate cancer aggressiveness. ( 21559935 )
2011
16
Fine-mapping of prostate cancer aggressiveness loci on chromosome 7q22-35. ( 20945404 )
2011
17
The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. ( 21900597 )
2011
18
Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. ( 21135144 )
2011
19
Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. ( 20615892 )
2010
20
Cytokine genetic polymorphisms and prostate cancer aggressiveness. ( 19474090 )
2009
21
Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. ( 19683746 )
2009
22
Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? ( 19627283 )
2009
23
Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. ( 18519765 )
2008
24
Prostate specific antigen density correlates with features of prostate cancer aggressiveness. ( 17222621 )
2007
25
Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. ( 12563560 )
2003
26
Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans. ( 11535545 )
2001
27
Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. ( 8012984 )
1994

Variations for Prostate Cancer, Hereditary, 7

Expression for Prostate Cancer, Hereditary, 7

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 7.

Pathways for Prostate Cancer, Hereditary, 7

GO Terms for Prostate Cancer, Hereditary, 7

Sources for Prostate Cancer, Hereditary, 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....